RLL may corner 15 % of market for generic Augmentin suspension
With Ranbaxy Laboratories Ltd getting the final approval for the suspension form of generic Augmentin (market of USD 272m) and Teva Pharmaceuticals not expected to pre-empt Ranbaxy, the Indian MNC is expected to gain a market share of at least 15 per cent for this dosage.

Stadmed launches new products, to enter the export market
KOLKATA-based Stadmed Limited, one of the leading pharmaceutical houses of the region has launched a set of advanced molecules targeting different therapeutic segments.

Dr Palep’s develops Collasyn
Dr Palep’s Medical Research Foundation, which developed a drug for cardiac treatment called Deehghayu (Terminalia Arjuna), has improved the drug treat menupause, osteoporosis and diabetes mellitius.